The cardiogenomics market size has grown rapidly in recent years. It will grow from $1.74 billion in 2025 to $2.02 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, advancements in genetic testing technologies, growth in clinical genomics research, wider availability of molecular diagnostics, rising awareness of inherited heart conditions.
The cardiogenomics market size is expected to see rapid growth in the next few years. It will grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing demand for personalized cardiac care, expansion of precision medicine initiatives, rising investments in genomic research, growing adoption of AI-driven genomic analysis, increased integration of genomics into routine cardiology practice. Major trends in the forecast period include increasing adoption of genetic risk profiling in cardiology, rising use of next-generation sequencing in heart disease research, growing integration of bioinformatics platforms, expansion of personalized cardiovascular treatment approaches, enhanced focus on preventive genomic screening.
The growing demand for personalized medicine is expected to drive the cardiogenomics market in the coming years. Personalized medicine tailors prevention, diagnosis, and treatment strategies to an individual’s genetic, environmental, and lifestyle factors. This demand is fueled by advances in genomics, which provide a deeper understanding of individual genetic variations, enabling precise, targeted treatments that improve patient outcomes and reduce trial-and-error in therapies. Cardiogenomics supports personalized medicine by using genetic insights to customize cardiovascular disease prevention, diagnosis, and treatment for each individual’s unique genetic profile. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022, including seven cancer drugs and three for other conditions. The rising adoption of personalized medicine is therefore propelling the growth of the cardiogenomics market.
Leading companies in the cardiogenomics market are developing innovative solutions, such as oncogenomics, to enhance early detection and personalized treatment of cardiovascular-related cancers. Oncogenomics studies cancer-related genes and mutations to understand cancer development, enabling targeted therapies and personalized treatment approaches. For instance, in April 2025, Fortis Healthcare Ltd., an India-based healthcare company, launched the Fortis Institute of Genomic Medicine to advance genetic research and personalized medicine. The institute promotes early disease detection, precise diagnosis, and personalized treatment across specialties including oncology, cardiology, and neurology. It supports targeted therapies, improves treatment outcomes, and enables preventive care for hereditary conditions, advancing precision medicine through a multidisciplinary team and innovative technologies.
In March 2025, Tempus AI Inc., a US-based technology company, acquired Ambry Genetics Corporation for an undisclosed sum. Through this acquisition, Tempus AI aims to leverage genetic testing and AI-driven data to expand its precision medicine capabilities, improve patient outcomes, and deliver comprehensive, personalized healthcare across multiple disease areas. Ambry Genetics Corporation is a US-based company providing genetic testing and precision medicine services, including cardiogenomics.
Major companies operating in the cardiogenomics market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., ARUP Laboratories, BGI Genomics Co. Ltd., Invitae Corporation, GeneDx Inc., Helix OpCo LLC, SOPHiA GENETICS SA, Baylor Genetics, Blueprint Genetics, Novogenia GmbH, Veritas Genetics, Dante Genomics, Gene by Gene Ltd., GENinCode Plc., UAB Cardiogenomics Clinic.
North America was the largest region in the cardiogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the cardiogenomics market by increasing costs of imported sequencing instruments, reagents, diagnostic kits, and bioinformatics hardware used in genomic testing workflows. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported advanced genomics equipment, while Asia-Pacific faces cost pressure on reagent supply chains. These tariffs are raising testing costs and slowing laboratory expansion. However, they are also driving local reagent manufacturing, regional sequencing platform development, and increased investment in domestic genomics infrastructure.
The cardiogenomics market research report is one of a series of new reports that provides cardiogenomics market statistics, including cardiogenomics industry global market size, regional shares, competitors with a cardiogenomics market share, detailed cardiogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the cardiogenomics industry. This cardiogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiogenomics is the study of how variations in an individual’s genetic makeup affect the risk, onset, and progression of cardiovascular diseases. It is essential for enabling personalized prevention, accurate diagnosis, and targeted treatment strategies to improve heart health outcomes.
The main product types in cardiogenomics include testing kits, reagents, instruments, software, and services. Testing kits are packaged tools and consumables designed to perform specific genetic tests. The technologies used include next-generation sequencing, polymerase chain reaction, microarrays, and others. Applications cover congenital heart diseases, cardiomyopathies, arrhythmias, coronary artery disease, and more, serving end users such as hospitals and clinics, diagnostic laboratories, research institutes, and other relevant organizations.
The cardiogenomics market consists of revenues earned by entities by providing services such as genetic testing and screening, risk assessment and prediction, and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiogenomics market also includes sales of cardiogenomic testing panels, genetic testing panels, and direct-to-consumer (DTC) genetic tests. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cardiogenomics market size is expected to see rapid growth in the next few years. It will grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing demand for personalized cardiac care, expansion of precision medicine initiatives, rising investments in genomic research, growing adoption of AI-driven genomic analysis, increased integration of genomics into routine cardiology practice. Major trends in the forecast period include increasing adoption of genetic risk profiling in cardiology, rising use of next-generation sequencing in heart disease research, growing integration of bioinformatics platforms, expansion of personalized cardiovascular treatment approaches, enhanced focus on preventive genomic screening.
The growing demand for personalized medicine is expected to drive the cardiogenomics market in the coming years. Personalized medicine tailors prevention, diagnosis, and treatment strategies to an individual’s genetic, environmental, and lifestyle factors. This demand is fueled by advances in genomics, which provide a deeper understanding of individual genetic variations, enabling precise, targeted treatments that improve patient outcomes and reduce trial-and-error in therapies. Cardiogenomics supports personalized medicine by using genetic insights to customize cardiovascular disease prevention, diagnosis, and treatment for each individual’s unique genetic profile. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022, including seven cancer drugs and three for other conditions. The rising adoption of personalized medicine is therefore propelling the growth of the cardiogenomics market.
Leading companies in the cardiogenomics market are developing innovative solutions, such as oncogenomics, to enhance early detection and personalized treatment of cardiovascular-related cancers. Oncogenomics studies cancer-related genes and mutations to understand cancer development, enabling targeted therapies and personalized treatment approaches. For instance, in April 2025, Fortis Healthcare Ltd., an India-based healthcare company, launched the Fortis Institute of Genomic Medicine to advance genetic research and personalized medicine. The institute promotes early disease detection, precise diagnosis, and personalized treatment across specialties including oncology, cardiology, and neurology. It supports targeted therapies, improves treatment outcomes, and enables preventive care for hereditary conditions, advancing precision medicine through a multidisciplinary team and innovative technologies.
In March 2025, Tempus AI Inc., a US-based technology company, acquired Ambry Genetics Corporation for an undisclosed sum. Through this acquisition, Tempus AI aims to leverage genetic testing and AI-driven data to expand its precision medicine capabilities, improve patient outcomes, and deliver comprehensive, personalized healthcare across multiple disease areas. Ambry Genetics Corporation is a US-based company providing genetic testing and precision medicine services, including cardiogenomics.
Major companies operating in the cardiogenomics market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., ARUP Laboratories, BGI Genomics Co. Ltd., Invitae Corporation, GeneDx Inc., Helix OpCo LLC, SOPHiA GENETICS SA, Baylor Genetics, Blueprint Genetics, Novogenia GmbH, Veritas Genetics, Dante Genomics, Gene by Gene Ltd., GENinCode Plc., UAB Cardiogenomics Clinic.
North America was the largest region in the cardiogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the cardiogenomics market by increasing costs of imported sequencing instruments, reagents, diagnostic kits, and bioinformatics hardware used in genomic testing workflows. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported advanced genomics equipment, while Asia-Pacific faces cost pressure on reagent supply chains. These tariffs are raising testing costs and slowing laboratory expansion. However, they are also driving local reagent manufacturing, regional sequencing platform development, and increased investment in domestic genomics infrastructure.
The cardiogenomics market research report is one of a series of new reports that provides cardiogenomics market statistics, including cardiogenomics industry global market size, regional shares, competitors with a cardiogenomics market share, detailed cardiogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the cardiogenomics industry. This cardiogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiogenomics is the study of how variations in an individual’s genetic makeup affect the risk, onset, and progression of cardiovascular diseases. It is essential for enabling personalized prevention, accurate diagnosis, and targeted treatment strategies to improve heart health outcomes.
The main product types in cardiogenomics include testing kits, reagents, instruments, software, and services. Testing kits are packaged tools and consumables designed to perform specific genetic tests. The technologies used include next-generation sequencing, polymerase chain reaction, microarrays, and others. Applications cover congenital heart diseases, cardiomyopathies, arrhythmias, coronary artery disease, and more, serving end users such as hospitals and clinics, diagnostic laboratories, research institutes, and other relevant organizations.
The cardiogenomics market consists of revenues earned by entities by providing services such as genetic testing and screening, risk assessment and prediction, and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiogenomics market also includes sales of cardiogenomic testing panels, genetic testing panels, and direct-to-consumer (DTC) genetic tests. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cardiogenomics Market Characteristics
3. Cardiogenomics Market Supply Chain Analysis
4. Global Cardiogenomics Market Trends and Strategies
5. Cardiogenomics Market Analysis of End Use Industries
7. Global Cardiogenomics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cardiogenomics Total Addressable Market (TAM) Analysis for the Market
9. Cardiogenomics Market Segmentation
10. Cardiogenomics Market Regional and Country Analysis
11. Asia-Pacific Cardiogenomics Market
12. China Cardiogenomics Market
13. India Cardiogenomics Market
14. Japan Cardiogenomics Market
15. Australia Cardiogenomics Market
16. Indonesia Cardiogenomics Market
17. South Korea Cardiogenomics Market
18. Taiwan Cardiogenomics Market
19. South East Asia Cardiogenomics Market
20. Western Europe Cardiogenomics Market
21. UK Cardiogenomics Market
22. Germany Cardiogenomics Market
23. France Cardiogenomics Market
24. Italy Cardiogenomics Market
25. Spain Cardiogenomics Market
26. Eastern Europe Cardiogenomics Market
27. Russia Cardiogenomics Market
28. North America Cardiogenomics Market
29. USA Cardiogenomics Market
30. Canada Cardiogenomics Market
31. South America Cardiogenomics Market
32. Brazil Cardiogenomics Market
33. Middle East Cardiogenomics Market
34. Africa Cardiogenomics Market
36. Cardiogenomics Market Competitive Landscape and Company Profiles
37. Cardiogenomics Market Other Major and Innovative Companies
40. Cardiogenomics Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Cardiogenomics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cardiogenomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cardiogenomics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiogenomics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Testing Kits; Reagents; Instruments; Software; Services2) By Technology: Next-Generation Sequencing; Polymerase Chain Reaction; Microarray; Other Technologies
3) By Application: Congenital Heart Diseases; Cardiomyopathies; Arrhythmias; Coronary Artery Disease; Other Applications
4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Other End-Users
Subsegments:
1) By Testing Kits: PCR (Polymerase Chain Reaction) kits; Microarray kits; NGS (Next Generation Sequencing) kits2) By Reagents: Enzymes; Probes; Buffers
3) By Instruments: Sequencers; Genotyping instruments; Microarray Scanners
4) By Software: Data Analysis Software; Reporting Platforms; Bioinformatics Tools
5) By Services: Genetic Testing Services; Counseling Services; Data Analysis Services
Companies Mentioned: Thermo Fisher Scientific Inc.; Laboratory Corporation of America Holdings (Labcorp); Quest Diagnostics Incorporated; Illumina Inc.; QIAGEN N.V.; Myriad Genetics Inc.; ARUP Laboratories; BGI Genomics Co. Ltd.; Invitae Corporation; GeneDx Inc.; Helix OpCo LLC; SOPHiA GENETICS SA; Baylor Genetics; Blueprint Genetics; Novogenia GmbH; Veritas Genetics; Dante Genomics; Gene by Gene Ltd.; GENinCode Plc.; UAB Cardiogenomics Clinic
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cardiogenomics market report include:- Thermo Fisher Scientific Inc.
- Laboratory Corporation of America Holdings (Labcorp)
- Quest Diagnostics Incorporated
- Illumina Inc.
- QIAGEN N.V.
- Myriad Genetics Inc.
- ARUP Laboratories
- BGI Genomics Co. Ltd.
- Invitae Corporation
- GeneDx Inc.
- Helix OpCo LLC
- SOPHiA GENETICS SA
- Baylor Genetics
- Blueprint Genetics
- Novogenia GmbH
- Veritas Genetics
- Dante Genomics
- Gene by Gene Ltd.
- GENinCode Plc.
- UAB Cardiogenomics Clinic
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.02 Billion |
| Forecasted Market Value ( USD | $ 3.57 Billion |
| Compound Annual Growth Rate | 15.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
